Actively Recruiting
EQUIP Trial Evaluating Estrogen with Androgen Receptor Inhibitors Versus Standard Hormone Therapy for Quality of Life in Men with Metastatic Hormone Sensitive Prostate Cancer
Led by Fred Hutchinson Cancer Center · Updated on 2026-11-02
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding estrogen via transdermal patches along with androgen receptor signaling inhibitors improves quality of life compared to standard hormone therapy in men with newly diagnosed or recurrent metastatic hormone sensitive prostate cancer. This phase II trial focuses on symptoms caused by standard treatment, such as hot flashes, fatigue, and bone and cardiovascular effects, by assessing if estrogen can help reduce these while controlling cancer progression. Participants are randomized into two groups. One group receives standard luteinizing hormone-releasing hormone LHRH analogues plus androgen receptor signaling inhibitors starting four weeks after LHRH initiation. The other group receives estrogen patches twice weekly in the first cycle, then adjusts dose based on testosterone levels, plus androgen receptor signaling inhibitors beginning four weeks after estrogen treatment starts. Treatment cycles repeat every 28 days without disease progression or unacceptable side effects. Participants undergo imaging scans, bone density tests, and blood tests throughout treatment. During the study, participants complete quality of life assessments and have their hot flash frequency monitored for at least 12 weeks. They also have regular CT or MRI scans, bone scans, DEXA scans, and blood sampling. After treatment ends, follow-up visits occur at 30 days and every six months for two years. Researchers measure changes in hot flash scores, bone health, metabolic markers, sleep quality, immune cell composition, and cancer progression over this period.
CONDITIONS
Brief Title
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Research Team
M
Michael Schweizer, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here